Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

Dr Simon Crabb - University of Southampton, Southampton, UK
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )
21 Feb 2022

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.

Prof Alfredo Berruti - University Of Brescia, Brescia, Italy
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )
21 Feb 2022

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
21 Feb 2022

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Feb 2022

Update on the new EUSOMA quality indicators for breast cancer

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )
3 Feb 2022

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz
Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )
1 Feb 2022

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom
Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )
27 Jan 2022

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea
Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )
27 Jan 2022

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )
27 Jan 2022

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA
HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )
27 Jan 2022

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2022